Medical - Devices
Compare Stocks
5 / 10Stock Comparison
VREX vs NNOX vs ATEC vs GEHC vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Devices
Medical - Healthcare Information Services
Medical - Devices
VREX vs NNOX vs ATEC vs GEHC vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Devices | Medical - Healthcare Information Services | Medical - Devices |
| Market Cap | $412M | $113M | $1.14B | $28.87B | $109.33B |
| Revenue (TTM) | $858M | $12M | $595M | $19.95B | $25.12B |
| Net Income (TTM) | $-83M | $-56M | $-125M | $1.50B | $3.25B |
| Gross Margin | 33.6% | -98.8% | 89.6% | 42.5% | 63.5% |
| Operating Margin | -3.7% | -469.7% | -9.6% | 12.5% | 22.4% |
| Forward P/E | 11.6x | — | 24.1x | 13.0x | 19.1x |
| Total Debt | $402M | $7M | $620M | $10.00B | $14.86B |
| Cash & Equiv. | $145M | $39M | $161M | $4.51B | $4.01B |
VREX vs NNOX vs ATEC vs GEHC vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 22 | May 26 | Return |
|---|---|---|---|
| Varex Imaging Corpo… (VREX) | 100 | 48.4 | -51.6% |
| Nano-X Imaging Ltd. (NNOX) | 100 | 23.4 | -76.6% |
| Alphatec Holdings, … (ATEC) | 100 | 60.9 | -39.1% |
| GE HealthCare Techn… (GEHC) | 100 | 108.7 | +8.7% |
| Stryker Corporation (SYK) | 100 | 116.8 | +16.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VREX vs NNOX vs ATEC vs GEHC vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VREX is the #2 pick in this set and the best alternative if value and momentum is your priority.
- Lower P/E (11.6x vs 24.1x)
- +13.6% vs NNOX's -66.6%
NNOX is the clearest fit if your priority is growth exposure.
- Rev growth 13.9%, EPS growth 15.7%, 3Y rev CAGR 105.3%
ATEC ranks third and is worth considering specifically for growth.
- 25.0% revenue growth vs VREX's 4.1%
Among these 5 stocks, GEHC doesn't own a clear edge in any measured category.
SYK carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 34 yrs, beta 0.52, yield 1.2%
- 179.2% 10Y total return vs ATEC's 215.7%
- Lower volatility, beta 0.52, Low D/E 66.3%, current ratio 1.89x
- PEG 1.28 vs GEHC's 20.66
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 25.0% revenue growth vs VREX's 4.1% | |
| Value | Lower P/E (11.6x vs 24.1x) | |
| Quality / Margins | 12.9% margin vs NNOX's -452.8% | |
| Stability / Safety | Beta 0.52 vs VREX's 1.77, lower leverage | |
| Dividends | 1.2% yield, 34-year raise streak, vs GEHC's 0.2%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +13.6% vs NNOX's -66.6% | |
| Efficiency (ROA) | 6.9% ROA vs NNOX's -31.6%, ROIC 11.4% vs -27.9% |
VREX vs NNOX vs ATEC vs GEHC vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
VREX vs NNOX vs ATEC vs GEHC vs SYK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SYK leads in 4 of 6 categories
VREX leads 0 • NNOX leads 0 • ATEC leads 0 • GEHC leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
SYK leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK is the larger business by revenue, generating $25.1B annually — 2041.6x NNOX's $12M. SYK is the more profitable business, keeping 12.9% of every revenue dollar as net income compared to NNOX's -4.5%. On growth, NNOX holds the edge at +13.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $858M | $12M | $595M | $20.0B | $25.1B |
| EBITDAEarnings before interest/tax | -$18M | -$46M | $4M | $3.3B | $6.3B |
| Net IncomeAfter-tax profit | -$83M | -$56M | -$125M | $1.5B | $3.2B |
| Free Cash FlowCash after capex | -$31M | -$47M | $7M | $1.5B | $4.3B |
| Gross MarginGross profit ÷ Revenue | +33.6% | -98.8% | +89.6% | +42.5% | +63.5% |
| Operating MarginEBIT ÷ Revenue | -3.7% | -4.7% | -9.6% | +12.5% | +22.4% |
| Net MarginNet income ÷ Revenue | -9.6% | -4.5% | -21.1% | +7.5% | +12.9% |
| FCF MarginFCF ÷ Revenue | -3.6% | -3.8% | +1.2% | +7.6% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.5% | +13.7% | -100.0% | +7.4% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.5% | +8.7% | +37.1% | -30.9% | +56.0% |
Valuation Metrics
Evenly matched — VREX and GEHC each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 13.9x trailing earnings, GEHC trades at a 59% valuation discount to SYK's 34.0x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.29x vs GEHC's 20.66x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $412M | $113M | $1.1B | $28.9B | $109.3B |
| Enterprise ValueMkt cap + debt − cash | $669M | $81M | $1.6B | $34.4B | $120.2B |
| Trailing P/EPrice ÷ TTM EPS | -5.78x | -1.90x | -7.83x | 13.95x | 33.98x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.56x | — | 24.13x | 12.95x | 19.06x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 20.66x | 2.29x |
| EV / EBITDAEnterprise value multiple | — | — | 3672.06x | 10.29x | 19.76x |
| Price / SalesMarket cap ÷ Revenue | 0.49x | 10.03x | 1.49x | 1.40x | 4.35x |
| Price / BookPrice ÷ Book value/share | 0.84x | 0.54x | 31.32x | 2.76x | 4.87x |
| Price / FCFMarket cap ÷ FCF | 21.92x | — | 410.02x | 19.17x | 25.53x |
Profitability & Efficiency
SYK leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-4 for ATEC. NNOX carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATEC's 17.21x. On the Piotroski fundamental quality scale (0–9), VREX scores 6/9 vs GEHC's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -17.1% | -35.5% | -4.4% | +14.4% | +15.0% |
| ROA (TTM)Return on assets | -7.6% | -31.6% | -15.8% | +4.1% | +6.9% |
| ROICReturn on invested capital | -2.6% | -27.9% | -12.6% | +13.3% | +11.4% |
| ROCEReturn on capital employed | -2.9% | -28.4% | -13.7% | +10.8% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 6 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.83x | 0.04x | 17.21x | 0.94x | 0.66x |
| Net DebtTotal debt minus cash | $257M | -$32M | $459M | $5.5B | $10.8B |
| Cash & Equiv.Liquid assets | $145M | $39M | $161M | $4.5B | $4.0B |
| Total DebtShort + long-term debt | $402M | $7M | $620M | $10.0B | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | -4.94x | -379.29x | -3.29x | 5.35x | 6.72x |
Total Returns (Dividends Reinvested)
SYK leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SYK five years ago would be worth $11,752 today (with dividends reinvested), compared to $661 for NNOX. Over the past 12 months, VREX leads with a +13.6% total return vs NNOX's -66.6%. The 3-year compound annual growth rate (CAGR) favors SYK at 0.8% vs NNOX's -52.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -15.6% | -38.9% | -63.8% | -23.3% | -17.8% |
| 1-Year ReturnPast 12 months | +13.6% | -66.6% | -41.0% | -9.8% | -24.5% |
| 3-Year ReturnCumulative with dividends | -55.3% | -89.4% | -49.4% | -19.6% | +2.4% |
| 5-Year ReturnCumulative with dividends | -58.4% | -93.4% | -46.4% | +6.5% | +17.5% |
| 10-Year ReturnCumulative with dividends | -65.1% | -96.1% | +215.7% | +6.5% | +179.2% |
| CAGR (3Y)Annualised 3-year return | -23.6% | -52.7% | -20.3% | -7.0% | +0.8% |
Risk & Volatility
Evenly matched — GEHC and SYK each lead in 1 of 2 comparable metrics.
Risk & Volatility
SYK is the less volatile stock with a 0.52 beta — it tends to amplify market swings less than VREX's 1.77 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GEHC currently trades 70.7% from its 52-week high vs NNOX's 29.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.77x | 1.75x | 0.74x | 1.32x | 0.52x |
| 52-Week HighHighest price in past year | $14.56 | $5.86 | $23.29 | $89.77 | $404.87 |
| 52-Week LowLowest price in past year | $6.76 | $1.66 | $6.85 | $58.75 | $284.97 |
| % of 52W HighCurrent price vs 52-week peak | +67.5% | +29.5% | +32.3% | +70.7% | +70.5% |
| RSI (14)Momentum oscillator 0–100 | 51.7 | 37.6 | 33.4 | 31.4 | 26.6 |
| Avg Volume (50D)Average daily shares traded | 291K | 1.4M | 3.1M | 4.4M | 2.1M |
Analyst Outlook
SYK leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: VREX as "Buy", NNOX as "Buy", ATEC as "Buy", GEHC as "Buy", SYK as "Buy". Consensus price targets imply 940.5% upside for NNOX (target: $18) vs 32.3% for GEHC (target: $84). For income investors, SYK offers the higher dividend yield at 1.18% vs GEHC's 0.22%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $14.50 | $18.00 | $19.71 | $84.00 | $389.62 |
| # AnalystsCovering analysts | 6 | 5 | 18 | 18 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +0.2% | +1.2% |
| Dividend StreakConsecutive years of raises | — | — | — | 3 | 34 |
| Dividend / ShareAnnual DPS | — | — | — | $0.14 | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +0.7% | 0.0% |
SYK leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
VREX vs NNOX vs ATEC vs GEHC vs SYK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VREX or NNOX or ATEC or GEHC or SYK a better buy right now?
For growth investors, Alphatec Holdings, Inc.
(ATEC) is the stronger pick with 25. 0% revenue growth year-over-year, versus 4. 1% for Varex Imaging Corporation (VREX). GE HealthCare Technologies Inc. (GEHC) offers the better valuation at 13. 9x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate Varex Imaging Corporation (VREX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VREX or NNOX or ATEC or GEHC or SYK?
On trailing P/E, GE HealthCare Technologies Inc.
(GEHC) is the cheapest at 13. 9x versus Stryker Corporation at 34. 0x. On forward P/E, Varex Imaging Corporation is actually cheaper at 11. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus GE HealthCare Technologies Inc. 's 20. 66x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — VREX or NNOX or ATEC or GEHC or SYK?
Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +17.
5%, compared to -93. 4% for Nano-X Imaging Ltd. (NNOX). Over 10 years, the gap is even starker: ATEC returned +215. 7% versus NNOX's -96. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VREX or NNOX or ATEC or GEHC or SYK?
By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.
52β versus Varex Imaging Corporation's 1. 77β — meaning VREX is approximately 239% more volatile than SYK relative to the S&P 500. On balance sheet safety, Nano-X Imaging Ltd. (NNOX) carries a lower debt/equity ratio of 4% versus 17% for Alphatec Holdings, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — VREX or NNOX or ATEC or GEHC or SYK?
By revenue growth (latest reported year), Alphatec Holdings, Inc.
(ATEC) is pulling ahead at 25. 0% versus 4. 1% for Varex Imaging Corporation (VREX). On earnings-per-share growth, the picture is similar: Nano-X Imaging Ltd. grew EPS 15. 7% year-over-year, compared to -45. 3% for Varex Imaging Corporation. Over a 3-year CAGR, NNOX leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VREX or NNOX or ATEC or GEHC or SYK?
Stryker Corporation (SYK) is the more profitable company, earning 12.
9% net margin versus -474. 3% for Nano-X Imaging Ltd. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -502. 9% for NNOX. At the gross margin level — before operating expenses — ATEC leads at 69. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VREX or NNOX or ATEC or GEHC or SYK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus GE HealthCare Technologies Inc. 's 20. 66x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Varex Imaging Corporation (VREX) trades at 11. 6x forward P/E versus 24. 1x for Alphatec Holdings, Inc. — 12. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NNOX: 940. 5% to $18. 00.
08Which pays a better dividend — VREX or NNOX or ATEC or GEHC or SYK?
In this comparison, SYK (1.
2% yield), GEHC (0. 2% yield) pay a dividend. VREX, NNOX, ATEC do not pay a meaningful dividend and should not be held primarily for income.
09Is VREX or NNOX or ATEC or GEHC or SYK better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
52), 1. 2% yield, +179. 2% 10Y return). Nano-X Imaging Ltd. (NNOX) carries a higher beta of 1. 75 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +179. 2%, NNOX: -96. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VREX and NNOX and ATEC and GEHC and SYK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: VREX is a small-cap quality compounder stock; NNOX is a small-cap quality compounder stock; ATEC is a small-cap high-growth stock; GEHC is a mid-cap deep-value stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while VREX, NNOX, ATEC, GEHC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.